Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Ordinary shares, nominal value 0.002 GBP per share
-
Shares outstanding
-
145,993,531
-
Total 13F shares
-
74,581,035
-
Share change
-
+2,707,155
-
Total reported value
-
$669,057,512
-
Price per share
-
$8.97
-
Number of holders
-
40
-
Value change
-
+$23,146,015
-
Number of buys
-
17
-
Number of sells
-
21
Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) as of Q1 2022
As of 31 Mar 2022,
Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
74,581,035 shares.
The largest 10 holders included
Medicxi Ventures Management (Jersey) Ltd, Index Venture Life Associates VI Ltd, GENERAL ATLANTIC, L.P., JANUS HENDERSON GROUP PLC, Vida Ventures Advisors, LLC, RA CAPITAL MANAGEMENT, L.P., OUP Management Co., LLC, PRICE T ROWE ASSOCIATES INC /MD/, Cormorant Asset Management, LP, and Samsara BioCapital, LLC.
This page lists
40
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.